Patents Assigned to Covx Technologies Ireland Limited
-
Publication number: 20180362519Abstract: The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.Type: ApplicationFiled: January 27, 2017Publication date: December 20, 2018Applicants: PFIZER INC., CovX Technologies Ireland LimitedInventors: Chakrapani SUBRAMANYAM, Lawrence N. TUMEY, Longfei XIE, Carolyn LEVERETT, Beth C. VETELINO, Sai Chetan K. SUKURU, Sarah HUDSON, Venkata Ramana DOPPALAPUDI, Abhijit S. BHAT
-
Patent number: 9163227Abstract: The present invention provides a composition of the formula: [FGF21-1st Linker]-[Ab]-[2nd-Linker-Ex4]; wherein FGF21 is an FGF21 homologue; and Ex4 is an Exendin4 homologue; and Ab is an aldolase catalytic antibody or antigen binding portion thereof; and the 1st linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2nd linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.Type: GrantFiled: December 12, 2012Date of Patent: October 20, 2015Assignee: COVX TECHNOLOGIES IRELAND LIMITEDInventors: Gopinath Vedachalam Annathur, Palani Balu, Rory Francis Finn, Jie Huang, Olivier Alexandre Laurent, Nancy Jane Levin, Nicholas Gary Luksha, Joseph Patrick Martin, Jr., Haim Moskowitz, Moorthy Sitharamaiah Suriyanarayana Palanki, Mark John Pozzo, Gregory Allan Waszak, Jin Xie
-
Patent number: 8937048Abstract: The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules.Type: GrantFiled: August 27, 2012Date of Patent: January 20, 2015Assignee: Covx Technologies Ireland, LimitedInventors: Venkata Ramana Doppalapudi, Jing-Yu Lai, Bin Liu, Dingguo Liu, Joel Desharnais, Abhijit Suresh Bhat, Yanwen Fu, Bryan Douglas Oates, Gang Chen, Curt William Bradshaw
-
Patent number: 8741291Abstract: The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL?) comprising K188 according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.Type: GrantFiled: November 28, 2011Date of Patent: June 3, 2014Assignee: Covx Technologies Ireland, LimitedInventors: Abhijit Suresh Bhat, Curt William Bradshaw, Olivier Alexandre Laurent, Alice Lee, Richard Ryan Preston, David Tumelty, Lauren Diane Wood, Wei Hong Yu
-
Patent number: 8722622Abstract: The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.Type: GrantFiled: November 4, 2011Date of Patent: May 13, 2014Assignees: COVX Technologies Ireland, Limited, Pfizer Inc.Inventors: Tapan Kanti Das, Tamara Shafer Hodge, Tetsuya Ishino, Nancy Jane Levin, Moorthy Sitharamaiah Suriyanarayana Palanki, Erin Kristen Parsons, Bernard Norman Violand
-
Publication number: 20130323234Abstract: The present invention relates to a polypeptide comprising 7 ?-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first ?-helix sequentially located on the EF chain between ?-strands E and F, wherein the ?-strands are arranged so as to form a first ?-sheet comprising ?-strands A, B, D, and E, and a second ?-sheet comprising ?-strands C, F and G, said first and second ?-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between ?-strands E and F comprises the sequence X1-X2-X3-X4-K5H6 (SEQ ID NO:98), and X1, X3 and X4 are each independently any amino acid residue, characterized in that X2 is selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereofType: ApplicationFiled: January 7, 2013Publication date: December 5, 2013Applicant: COVX TECHNOLOGIES IRELAND LIMITEDInventor: Covx Technologies Ireland Limited
-
Publication number: 20120282279Abstract: The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.Type: ApplicationFiled: November 4, 2011Publication date: November 8, 2012Applicants: COVX TECHNOLOGIES IRELAND LIMITED, PFIZER INCInventors: Tapan Kanti Das, Tamara Shafer Hodge, Tetsuya Ishino, Nancy Jane Levin, Moorthy Sitharamaiah Suriyanarayana Palanki, Erin Kristan Parsons, Bernard Norman Violand
-
Publication number: 20120201809Abstract: The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL?) comprising K188 according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.Type: ApplicationFiled: November 28, 2011Publication date: August 9, 2012Applicant: COVX TECHNOLOGIES IRELAND, LIMITEDInventors: Abhijit Suresh Bhat, Curt William Bradshaw, Olivier Alexandre Laurent, Alice Lee, Richard Ryan Preston, David Tumelty, Lauren Diane Wood, Wei Hong Yu
-
Patent number: 7521425Abstract: The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.Type: GrantFiled: March 3, 2006Date of Patent: April 21, 2009Assignee: Covx Technologies Ireland LimitedInventors: Curt W. Bradshaw, Venkata Ramana Doppalapudi, Jing-Yu Lai, John Rizzo